Approximately 40% of gastric and gastroesophageal junction (GEJ) adenocarcinoma patients present with metastasis, and half of patients with localized disease progress to metastatic disease…
The gastroesophageal cancer therapy market (including gastric, gastroesophageal junction, and esophageal cancer) is rapidly evolving and experiencing substantial growth, largely driven by the…
China has the highest incidence of gastroesophageal cancer in the world. Chemotherapy is the main treatment, although targeted therapies such as trastuzumab (an anti-HER2 MAb for HER2-positive…
Epidemiology Data Slicer
Metastatic esophageal cancer remains a subpopulation for which few treatment options exist. For decades, treatment was limited to chemotherapy-based regimens such as FOLFOX and DCF, but the recent…
Clarivate Epidemiology’s coverage of esophageal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of esophageal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of esophageal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of esophageal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of esophageal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of esophageal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…